ALX Oncology Set for Breakout with Key 2026 Trial Results
AI Prediction of ALX Oncology Holdings Inc. (ALXO)
ALX Oncology is poised for significant development advancements in 2026 with key clinical trial results expected for its lead assets, evorpacept and ALX2004. The company’s focus on oncology, particularly using biomarker-driven strategies, positions it well within the biotech sector for potential growth.
ALX Oncology, a clinical-stage biotech firm, is advancing a promising pipeline with lead assets like evorpacept and ALX2004 targeting significant unmet needs in oncology. Evorpacept's upcoming data from Phase 2 trials in breast and colorectal cancers, alongside ALX2004’s Phase 1 trials in EGFR-expressing solid tumors, are pivotal for the company’s near-term valuation. The strategic focus on biomarker-driven treatments and partnerships with leading pharmaceuticals enhances ALX Oncology’s potential to deliver substantial investor returns. These catalysts, expected in the latter half of 2026, make ALX Oncology a compelling watch for biotech investors.
ALXO Report Information
Prediction Date2026-03-09
Close @ Prediction$2.21
Mkt Cap221m
IPO DateN/a
AI-derived Information
Recent News for ALXO
- Apr 17, 4:05 pm — ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules (GlobeNewswire)
- Apr 13, 8:30 am — ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer (GlobeNewswire)
- Mar 10, 11:38 am — GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma (Zacks)
- Mar 10, 11:09 am — EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y (Zacks)
- Mar 9, 10:23 am — Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study (Zacks)
- Mar 7, 8:25 am — ALX Oncology initiated with a Buy at UBS (TipRanks)
- Mar 6, 10:26 am — LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? (Zacks)
- Mar 6, 9:57 am — QURE Stock Crashes 32% in a Week: Here's What You Should Know (Zacks)
- Mar 6, 8:27 am — Mirum Completes Enrollment & Screening in Liver Disease Studies (Zacks)
- Mar 5, 9:18 am — CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data (Zacks)
- Mar 5, 5:07 am — ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised) (Zacks)
- Mar 4, 8:03 am — ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Zacks)
NDAPR (News-Driven AI Prediction Revision) events for ALXO
-
Apr 17, 5:53 pmRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason: Q3 2026 breast data catalyst unchangedRationale: Management hiring and inducement equity are non-catalytic; Catalyst progress. the Q3 2026 ASPEN-09 interim data remains the key thesis driver.
-
Apr 13, 8:40 amRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason: Leadership enhancementRationale: Catalyst progress with strengthened leadership for upcoming clinical milestones.
-
Mar 10, 12:13 pmRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason:Rationale: No new data impacts the current prediction or investment thesis.
-
Mar 9, 11:32 amRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason:Rationale: No new data impacts ALXO's catalyst or financial outlook.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest